Bulk Manufacturer of Controlled Substances Application: S&B Pharma LLC, 10819-10820 [2022-04062]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 38 / Friday, February 25, 2022 / Notices
SUPPLEMENTARY INFORMATION:
INTERNATIONAL TRADE
COMMISSION
[Inv. No. 337–TA–1302]
Certain Cellular Base Station
Communication Equipment,
Components Thereof, and Products
Containing Same; Institution of
Investigation; Institution of
Investigation Pursuant to 19 U.S.C.
1337
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
January 19, 2022, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Apple Inc. of Cupertino,
California. The complaint alleges
violations of section 337 based upon the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain cellular base station
communication equipment, components
thereof, and products containing same
by reason of infringement of certain
claims of U.S. Patent No. 9,882,282
(‘‘the ’282 patent’’); U.S. Patent No.
10,263,340 (‘‘the ’340 patent’’); and U.S.
Patent 9,667,290 (‘‘the ’290 patent’’).
The complaint further alleges that an
industry in the United States exists as
required by the applicable Federal
Statute.
The complainants request that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist order.
ADDRESSES: The complaint, except for
any confidential information contained
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, Office of Unfair
Import Investigations, U.S. International
Trade Commission, telephone (202)
205–2560.
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
16:44 Feb 24, 2022
Jkt 256001
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2021).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
February 18, 2022, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (2) by reason of
infringement of one or more of claims
1–3, 11, and 12 of the ’282 patent;
claims 1–4, 6–10, 18, 19, and 21 of the
’340 patent; and claims 1–6, 13, and 14
of the ’290 patent, and whether an
industry in the United States exists as
required by subsection (a)(2) of section
337;
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘cellular base station
communication equipment, specifically
mmWave antenna radio units and radio
baseband units, components thereof,
and products containing same’’;
(3) Pursuant to Commission Rule
210.50(b)(l), 19 CFR 210.50(b)(1), the
presiding administrative law judge shall
take evidence or other information and
hear arguments from the parties or other
interested persons with respect to the
public interest in this investigation, as
appropriate, and provide the
Commission with findings of fact and a
recommended determination on this
issue, which shall be limited to the
statutory public interest factors set forth
in 19 U.S.C. l337(d)(l), (f)(1), (g)(1);
(4) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainants are: Apple Inc.,
One Apple Park Way, Cupertino, CA
95014.
(b) The respondent is the following
entity alleged to be in violation of
section 337, and is the party upon
which the complaint is to be served:
Ericsson AB, Torshamnsgatan 23, Kista,
16480 Stockholm, Sweden.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
10819
Telefonaktiebolaget LM Ericsson,
Torshamnsgatan 21, Kista, SE–164 83,
Stockholm, Sweden.
Ericsson Inc., 6300 Legacy Drive,
Plano, TX 75024.
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW, Suite
401, Washington, DC 20436; and
(5) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondent in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainants of
the complaint and the notice of
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a/the respondent to file a
timely response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: February 18, 2022.
Jessica Mullan,
Acting Supervisory Attorney.
[FR Doc. 2022–03957 Filed 2–24–22; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–966]
Bulk Manufacturer of Controlled
Substances Application: S&B Pharma
LLC
Drug Enforcement
Administration, Justice.
AGENCY:
E:\FR\FM\25FEN1.SGM
25FEN1
10820
ACTION:
Federal Register / Vol. 87, No. 38 / Friday, February 25, 2022 / Notices
Notice of application.
DEPARTMENT OF JUSTICE
S&B Pharma LLC has applied
to be registered as a bulk manufacturer
of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 26, 2022. Such persons
may also file a written request for a
hearing on the application on or before
April 26, 2022.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on December 24, 2021,
S&B Pharma LLC, 405 South Motor
Avenue, Azusa, California 91702,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
lotter on DSK11XQN23PROD with NOTICES1
Gamma Hydroxybutyric
Acid.
Marihuana .....................
Tetrahydrocannabinols
Amphetamine ...............
Methamphetamine ........
Lisdexamfetamine ........
Methylphenidate ...........
Pentobarbital ................
4-Anilino-N-Phenethyl4-Piperidine (ANPP).
Tapentadol ....................
Fentanyl ........................
Drug
code
Schedule
2010
I
7360
7370
1100
1105
1205
1724
2270
8333
I
I
II
II
II
II
II
II
9780
9801
II
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use
intermediates for formulation and
analytical development purposes or for
sale to its customers. In reference to dug
codes 7360 (Marihuana), and 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture these drugs
as synthetic. No other activities for these
drug codes are authorized for this
registration.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022–04062 Filed 2–24–22; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
16:44 Feb 24, 2022
Jkt 256001
Controlled substance
Drug
code
Schedule
Drug Enforcement Administration
[Docket No. DEA–974]
Bulk Manufacturer of Controlled
Substances Application: Cedarburg
Pharmaceuticals
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Cedarburg Pharmaceuticals
has applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplemental Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 26, 2022. Such persons
may also file a written request for a
hearing on the application on or before
April 26, 2022.
ADDRESSES: DEA requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to https://
www.regulations.gov and follow the
online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.’’
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on August 27, 2021,
Cedarburg Pharmaceuticals, 870 Badger
Circle, Grafton, Wisconsin 53024–0000,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUMMARY:
Controlled substance
Lysergic Acid
Diethylamide.
Tetrahydrocannabinols
4-Bromo-2,5Dimethoxyphenethylamine.
3,4Methylenediocyamphetamine.
PO 00000
Frm 00057
Fmt 4703
Drug
code
Schedule
7315
I
7370
7392
I
I
7400
I
Sfmt 4703
3.4Methylenedioxymethamphetamine.
5-Methoxy-N-Ndimethltryptamine.
Dimethyltryptamine .......
Psilocybin .....................
Psilocyn ........................
Methylphenidate ...........
Nabilone .......................
4-Anilino-N-Phenethyl4-Piperidine (ANPP).
Fentanyl ........................
7405
I
7431
I
7435
7437
7438
1724
7379
8333
I
I
I
II
II
II
9801
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use
intermediates or for sale to its
customers. In reference to the drug code
7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture as
synthetic. No other activity for this drug
code is authorized for this registration.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022–04064 Filed 2–24–22; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–964]
Bulk Manufacturer of Controlled
Substances Application: Synthcon
LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Synthcon LLC has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTAL
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 26, 2022. Such persons
may also file a written request for a
hearing on the application on or before
April 26, 2022.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUMMARY:
In
accordance with 21 CFR 1301.33(a), this
is notice that on December 2, 2021,
SUPPLEMENTARY INFORMATION:
E:\FR\FM\25FEN1.SGM
25FEN1
]]>Agencies
[Federal Register Volume 87, Number 38 (Friday, February 25, 2022)]
[Notices]
[Pages 10819-10820]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04062]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-966]
Bulk Manufacturer of Controlled Substances Application: S&B
Pharma LLC
AGENCY: Drug Enforcement Administration, Justice.
[[Page 10820]]
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: S&B Pharma LLC has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before April 26, 2022.
Such persons may also file a written request for a hearing on the
application on or before April 26, 2022.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on December 24, 2021, S&B Pharma LLC, 405 South Motor
Avenue, Azusa, California 91702, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.............. 2010 I
Marihuana.............................. 7360 I
Tetrahydrocannabinols.................. 7370 I
Amphetamine............................ 1100 II
Methamphetamine........................ 1105 II
Lisdexamfetamine....................... 1205 II
Methylphenidate........................ 1724 II
Pentobarbital.......................... 2270 II
4-Anilino-N-Phenethyl-4-Piperidine 8333 II
(ANPP).
Tapentadol............................. 9780 II
Fentanyl............................... 9801 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for the internal use intermediates for formulation and
analytical development purposes or for sale to its customers. In
reference to dug codes 7360 (Marihuana), and 7370
(Tetrahydrocannabinols), the company plans to bulk manufacture these
drugs as synthetic. No other activities for these drug codes are
authorized for this registration.
Matthew J. Strait,
Deputy Assistant Administrator.
[FR Doc. 2022-04062 Filed 2-24-22; 8:45 am]
BILLING CODE 4410-09-P
